Delivery Order SPE2DB24D2205-SPE2DB25FECDA
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,587.40 to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. This firm fixed-price delivery order, issued on September 15, 2025, with an ultimate completion date of October 6, 2025, represents a non-set-aside competitive award to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $46,934.16 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin on July 18, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $2,793.70 and an ultimate completion date of September 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,823.64 for 50-unit vials of Xeomin, a botulinum toxin injection used for therapeutic and cosmetic applications. This firm fixed-price delivery order, awarded on August 29, 2025, with an ultimate completion date of September 22, 2025, represents a non-competitive set-aside award issued under the company's larger indefinite delivery contract. The work will be performed at AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $9,118.20 to AmerisourceBergen Drug Corp for the supply of Xeomin 50 Unit Vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, utilizes firm fixed pricing with no set-aside designation, indicating open and competitive procurement. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xeomin 100 Unit Vials with a ceiling value of $35,535.50 under a firm fixed-price contract. This non-set-aside award is scheduled for completion by October 8, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a competitively awarded procurement action sourced through the company's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,968.50 to AmerisourceBergen Drug Corp for the supply of Xeomin 100 unit vials. This firm fixed-price contract was competitively awarded without set-aside designation and carries an ultimate completion date of May 23, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999 and...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FECDADelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,676.22 for 100-unit vials of Xeomin on May 9, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively procured delivery order under DLA's broader pharmaceutical supply chain, reflecting the agency's ongoing medical procurement needs for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive prime contract vehicle enables the contractor to supply a wide range of pharmaceutical products and medical commodities to support military healthcare operations globally. Xeomin, a botulinum toxin therapeutic, aligns with AmerisourceBergen's extensive portfolio of specialty medications and brand-name pharmaceuticals that serve Defense Health Agency requirements and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 5/9/25 |